Your AI-Trained Oncology Knowledge Connection!
Findings from an updated safety and efficacy analysis of the phase 3 KEYNOTE-775 trial were consistent with the primary analysis and highlighted notable improvements in outcomes among patients with advanced endometrial cancer treated with lenvatinib and pembrolizumab vs physician’s choice.
Patients with newly diagnosed ovarian cancer with or without a high risk of progression experienced a progression-free survival benefit from treatment with maintenance rucaparib compared with placebo regardless of molecular characteristics.
Overall survival remained durable in patients with metastatic non–small cell lung cancer when tremelimumab was added to durvalumab plus chemotherapy in the frontline setting.
Despite the combination of enzalutamide plus abiraterone acetate and prednisolone (AAP) falling short in patients with metastatic hormone-sensitive prostate cancer, although androgen deprivation therapy plus AAP resulted in a clinically meaningful overall survival benefit.
Patients with localized recall cell carcinoma did not have improved disease-free survival with adjuvant nivolumab plus ipilimumab vs placebo.
Pembrolizumab plus chemoradiation did not meet statistically significant improvement in event-free survival for patients with locally advanced head and neck squamous cell carcinoma.
Results from a blood-based multi-cancer detection test potentially indicated the presence of cancer.
Results from the phase 3 RATIONALE-301 trial showed improved overall survival for patients who were given frontline tislelizumab for unresectable hepatocellular carcinoma.
At the 5-year mark, overall survival was improved with xevinapant plus standard chemoradiotherapy vs matched placebo in locally advanced head and neck squamous cell carcinoma.
Antitumor activity and safety of pembrolizumab plus abiraterone acetate appears to be sustained in chemotherapy-naïve castration-resistant prostate cancer.
Phase 3 data regarding perioperative nivolumab did not show recurrence-free survival benefit, but data from the study may help inform future research.
Data from the phase 3 IMmotion010 trial revealed no benefit of adjuvant atezolizumab vs placebo for resectable renal cell carcinoma.
Results of a phase 2 trial show favorable efficacy and tolerable safety of naporafenib in combination with rineterkib, trametinib, or ribociclib in previously treated, unresectable or metastatic melanoma.
Long-term follow-up of the phase 2 DESTINY-Gastric02 study revealed fam-trastuzumab deruxtecan-nxki continues to show promise in locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
The phase 2 AMEERA-3 trial revealed no progression-free survival benefit of amcenestrant vs physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor–positive, HER2-negative advanced breast cancer.
Progression-free survival and response results presented from the phase 3 TROPiCS-02 trial at 2022 ESMO indicated sacituzumab govitecan-hziy may be favorable vs physician’s choice of treatment for HER2-low or HER2 IHC0, hormone receptor¬–positive metastatic breast cancer.
Phase 1 data on efficacy and safety of ADP-A2M4CD8 in MAGE-A4–positive advanced metastatic disease shows promise at 2022 ESMO.
The nonsteroidal selective estrogen receptor modulator lasofoxifene resulted in better clinical benefit vs fulvestrant in patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutant metastatic breast cancer.
Findings from long-term follow-up of the EMPOWER-Cervical 1 study demonstrated that cemiplimab improved survival vs chemotherapy and resulted in a safety profile like other anti–PD-L1 agents.
Long-term results of a phase 2 study (NCT02211131) revealed consistent efficacy at 5 years with talimogene laherparepvec in stage IIIB to IVM1a melanoma.
Results from the LEAP-002 trial revealed extended median overall survival with lenvatinib monotherapy in patients with unresectable hepatocullar carcinoma.
Results of a phase 3 study appear to indicate better progression-free and overall survival outcomes with camrelizumab and rivoceranib vs sorafenib in unresectable hepatocellular carcinoma.
A phase 3 study presented at 2022 ESMO showed progression-free survival benefit of nirogacestat over placebo for patients with progressive desmoid tumors.
The addition of abemaciclib vs standard-of-care chemotherapy to trastuzumab numerically improved overall survival in women with hormone receptor–positive, HER2-positive advanced breast cancer.
Findings provided rationale to limit air pollution and highlighted the need for molecularly targeted lung cancer prevention due to particulate matter being revealed as a mechanistic driver for EGFR-positive NSCLC.
A randomized phase 3 trial presented at 2022 ESMO revealed better progression-free survival outcomes with tumor-infiltrating lymphocytes vs ipilimumab in stage IIIC/IV unresectable, treatment-refractory melanoma.
The CDK4/6 inhibitor dalpiciclib in combination with letrozole or anastrozole improved progression free survival in patients with treatment-naïve advanced breast cancer.
CLDN6-directed CAR T-cell therapy BNT211-01 showed clinical activity as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in relapsed/refractory advanced solid tumors.
Results from the phase 2 SYNERGY trial suggest little or no benefit of adding oleclumab to durvalumab and chemotherapy for advanced frontline triple-negative breast cancer.
Abemaciclib prolonged overall survival when added to a nonsteroidal aromatase inhibitor in hormone receptor–positive, HER2–negative breast cancer, according to updated findings from the MONARCH 3 trial presented at 2022 ESMO.
